P08.15 Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma patients

摘要

Introduction:Glioblastoma is the most aggressive adult primary malignant brain tumor and despite standard treatment the median survival is less than 15 months. Nearly all patients with glioblastoma experience relapse, at which stage most treatments have limited effect. A combination treatment with bevacizumab, an anti-angiogenic agent, has shown effect in approximately 30% of patients with relapse. We have recently identified upregulated renin-angiotensin system in patients not responding to bevacizumab therapy. The objectives of this study were to investigate if use of drugs inhibiting angiotensin II improved the effect of bevacizumab therapy and to analyse whether angiotensin II inhibition improved the effect of standard treatment.